Civitas Therapeutics Initiates Phase 2b Clinical Study of CVT-301, Inhaled L-dopa for Parkinson’s Disease

Published: Sep 05, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CHELSEA, Mass.--(BUSINESS WIRE)--Civitas Therapeutics, Inc., a biopharmaceutical company developing transformative therapeutics using the ARCUS® respiratory delivery platform, today announced the initiation of a Phase 2b clinical study of CVT-301, an inhaled formulation of levodopa (L-dopa). CVT-301 is being developed as an adjunct, as needed (PRN) therapy that will provide rapid and reliable relief from intermittent debilitating motor fluctuations (OFF episodes) that affect many Parkinson’s disease patients. This Phase 2 study will evaluate the efficacy and safety of CVT-301 in treating emergent OFF episodes during one month of continued use.

Help employers find you! Check out all the jobs and post your resume.

Back to news